Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3541272 | 1.00 | HSD17B10 (0.31) | HSD17B10SMN1; SMN2 | |
| SCHEMBL20752398 | 0.97 | — | — | |
| SCHEMBL644462 | 0.97 | — | — | |
| SCHEMBL8531022 | 0.89 | ALDH1A1 (0.33) | — | |
| SCHEMBL8531017 | 0.89 | ALDH1A1 (0.33) | — | |
| SCHEMBL8529793 | 0.86 | ALDH1A1 (0.35) | — | |
| SCHEMBL8529790 | 0.86 | ALDH1A1 (0.35) | — | |
| SCHEMBL22440292 | 0.76 | CA12 (0.30) | — | |
| SCHEMBL22282962 | 0.76 | — | — | |
| SCHEMBL14582189 | 0.76 | RECQL (0.48) | HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101573640-B | Interference film with acrylamide coating and method for producing same | 3M INNOVATIVE PROPERTIES CO | 2013-11-13 | — | — | CN | claimed |
| US-8120854-B2 | Substituted acrylamide polymer disposed between reflective layers; bonding strength; document counterfeiting prevention | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-02-21 | — | — | US | claimed |
| EP-2126616-A1 | INTERFERENCE FILMS HAVING ACRYLAMIDE LAYER AND METHOD OF MAKING SAME | 3M Innovative Properties Company (US) | 2009-12-02 | — | — | EP | claimed |
| WO-2008082935-A1 | INTERFERENCE FILMS HAVING ACRYLAMIDE LAYER AND METHOD OF MAKING SAME | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-07-10 | — | — | WO | claimed |
| US-20080160185-A1 | INTERFERENCE FILMS HAVING ACRYLAMIDE LAYER AND METHOD OF MAKING SAME | 3M INNOVATIVE PROPERTIES COMPANY | 2008-07-03 | — | — | US | claimed |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4548918-A2 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-111448190-B | Substituted indole compounds | 百时美施贵宝公司 | 2023-09-26 | — | — | CN | disclosed |
| WO-2023133943-A1 | CROSS-LINKED POLYAMIC ACID ESTER AND PREPARATION METHOD THEREFOR, POLYIMIDE COMPOSITION COMPRISING SAME, AND METHOD FOR PREPARING POLYIMIDE RESIN FILM | 深圳职业技术学院 | 2023-07-20 | — | — | WO | disclosed |
| CN-109843858-B | Certain chemical entities, compositions and methods | 润新生物公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-4135844-A1 | FUSED TRICYCLIC KRAS INHIBITORS | Incyte Corporation (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-115702025-A | Fused tricyclic KRAS inhibitors | 因赛特公司 | 2023-02-14 | — | — | CN | disclosed |
| US-6608203-B2 | Devoid of unwanted side effects | PFIZER INC. | 2003-08-19 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| US-20010039285-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2001-11-08 | — | — | US | disclosed |
| EP-1113007-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | PFIZER INC. (US) | 2001-07-04 | — | — | EP | disclosed |
| US-4239901-A | ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1980-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039285-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | HSD17B10 721/4885SMN1; SMN2 3840/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | HSD17B10 1253/4885SMN1; SMN2 2090/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | HSD17B10 1351/4885SMN1; SMN2 2424/4885 |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | HSD17B10 2884/4885SMN1; SMN2 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.